このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Nyrada マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

James Bonnar

最高経営責任者

AU$394.1k

報酬総額

CEO給与比率	74.7%
CEO在任期間	no data
CEOの所有権	0.08%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	4.8yrs

経営陣の近況

Shareholders Will Probably Not Have Any Issues With Nyrada Inc.'s (ASX:NYR) CEO Compensation

Nov 12

Recent updates

Shareholders Will Probably Not Have Any Issues With Nyrada Inc.'s (ASX:NYR) CEO Compensation

Nov 12

Companies Like Nyrada (ASX:NYR) Can Afford To Invest In Growth

Jan 10

We're Keeping An Eye On Nyrada's (ASX:NYR) Cash Burn Rate

Feb 23

CEO報酬分析

Nyrada の収益と比較して、James Bonnar の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	n/a	n/a	-AU$5m
Sep 30 2023	n/a	n/a	-AU$6m
Jun 30 2023	AU$394k	AU$294k	-AU$8m
Mar 31 2023	n/a	n/a	-AU$6m
Dec 31 2022	n/a	n/a	-AU$4m
Sep 30 2022	n/a	n/a	-AU$4m
Jun 30 2022	AU$464k	AU$274k	-AU$4m
Mar 31 2022	n/a	n/a	-AU$4m
Dec 31 2021	n/a	n/a	-AU$4m
Sep 30 2021	n/a	n/a	-AU$4m
Jun 30 2021	AU$378k	AU$277k	-AU$4m
Mar 31 2021	n/a	n/a	-AU$5m
Dec 31 2020	n/a	n/a	-AU$6m
Sep 30 2020	n/a	n/a	-AU$6m
Jun 30 2020	AU$302k	AU$275k	-AU$6m
Mar 31 2020	n/a	n/a	-AU$5m
Dec 31 2019	n/a	n/a	-AU$4m
Sep 30 2019	n/a	n/a	-AU$4m
Jun 30 2019	AU$306k	AU$250k	-AU$4m

報酬と市場: Jamesの総報酬 ($USD 262.41K ) は、 Australian市場 ($USD 296.24K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Jamesの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

James Bonnar

no data

在職期間

AU$394,059

報酬

Mr. James Bonnar has been Chief Executive Officer of Nyrada Inc. Mr. Bonnar had been Vice-President of R&D at Nyrada Inc. since February 2018. He joined Nyrada in February 2018, bringing over 20 years of e...

取締役

名称	ポジション	在職期間	報酬	所有権
John Moore	Non-Executive Chairman	5yrs	AU$215.04k	0.93% A$ 91.4k
Christopher Cox	Non-Executive Director	4.6yrs	AU$92.65k	0.78% A$ 77.0k
Marcus Frampton	Independent Non-Executive Director	5yrs	AU$92.65k	0.65% A$ 63.6k
Ian Dixon	Non-Executive Director	3.8yrs	AU$225.13k	5.7% A$ 560.6k
Rudiger Weseloh	Independent Non-Executive Director	5yrs	AU$85.21k	0.20% A$ 19.8k
Gisela Mautner	Non-Executive Director	1.8yrs	AU$68.27k	データなし
Gary Housley	Chairman of Scientific Advisory Board	no data	データなし	0.77% A$ 76.2k
Junichi Nabekura	Member of Scientific Advisory Board	no data	データなし	データなし
David Burke	Member of Scientific Advisory Board	no data	データなし	データなし
Gilles Lambert	Member of Scientific Advisory Board	no data	データなし	データなし
Jim Palmer	Member of Scientific Advisory Board	no data	データなし	データなし

4.8yrs

平均在職期間

経験豊富なボード: NYRの取締役会は経験豊富であると考えられます ( 4.8年の平均在任期間)。

Nyrada マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Shareholders Will Probably Not Have Any Issues With Nyrada Inc.'s (ASX:NYR) CEO Compensation

Nyrada Inc., Annual General Meeting, Nov 20, 2023

Less than half of directors are independent

Nyrada Inc., Annual General Meeting, Nov 21, 2022

Nyrada Inc. Announces Board Changes

Less than half of directors are independent

Recent updates

New major risk - Market cap size

Nyrada Inc. has filed a Follow-on Equity Offering in the amount of AUD 1.965 million.

First half 2024 earnings released: EPS: AU$0.001 (vs AU$0.017 loss in 1H 2023)

Shareholders Will Probably Not Have Any Issues With Nyrada Inc.'s (ASX:NYR) CEO Compensation

Full year 2023 earnings released: AU$0.05 loss per share (vs AU$0.025 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Share price stability

First half 2023 earnings released: AU$0.017 loss per share (vs AU$0.018 loss in 1H 2022)

Nyrada Inc., Annual General Meeting, Nov 20, 2023

Nyrada Inc. Provides Update on the Progress of Its Brain Injury Program

Less than half of directors are independent

Nyrada Inc., Annual General Meeting, Nov 21, 2022

Nyrada Inc. Announces Efficacy Study Published in Journal of Lipid Research

Full year 2022 earnings released: AU$0.03 loss per share (vs AU$0.03 loss in FY 2021)

Nyrada Inc. Announces Board Changes

Nyrada Inc. Provides Cholesterol-Lowering Program Update

Nyrada Inc. Unveils Target of Its Brain Injury Program as TRPC Ion Channels & Provides Phase I Study Update

European Patent to be Granted for Cholesterol-Lowering Drug of Nyrada Inc

Less than half of directors are independent

Nyrada Inc. Announces Its Newest Brain Injury Drug Candidate

Nyrada Inc. Announces Its Newest Brain Injury Drug Candidate

Companies Like Nyrada (ASX:NYR) Can Afford To Invest In Growth

Nyrada Inc Provides an Update on the Progress of its Brain Injury Program

Nyrada Inc Announces Encouraging Efficacy Results from Its in Vivo Study of NYX-PCSK9i Called called APOE*3-Leiden.CETP

Nyrada Inc Announces New Potent Cholesterol-Lowering Candidates

Nyrada Inc. announced that it expects to receive AUD 11 million in funding

We're Keeping An Eye On Nyrada's (ASX:NYR) Cash Burn Rate

Nyrada Inc. Releases Update on the Company's Two Drug Development Programs

Nyrada Inc. Secures Collaboration with Walter Reed Army Institute of Research and UNSW

Nyrada Reports Further Results from Cholesterol Study

New 90-day high: AU$0.45

New 90-day high: AU$0.28

New 90-day high: AU$0.23

Full year earnings released - AU$0.095 loss per share

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

マネジメント基準チェック /34